Home / Companies / Arcutis Biotherapeutics, Inc. / 14 Jun 2024
Arcutis Biotherapeutics, Inc.: meeting of 14 Jun 2024
Votes reported on Form N-PX, item by item
230 Form N-PX filers reported votes at the Arcutis Biotherapeutics, Inc. meeting of 14 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 57.3% of reported votes for; 68 filers withheld from or voted against at least one nominee.
417 vote records from 82 filers. 29 of the 82 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
317 vote records from 230 filers. 169 of the 218 filers that marked the item either way voted against management. 12 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
139 vote records from 82 filers. 0 of the 82 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | Against * | For |
| BlackRock and iShares | For | Against * | For |
| Fidelity | For | Against * | For |
| Dimensional | No report | Against * | No report |
| State Street and SPDR | For | For | For |
| American Century | Abstain or withhold * | Against * | For |
| Franklin Templeton | For | Against * | For |
| Invesco | For | Against * | For |
| Equitable | Abstain or withhold * | Against * | For |
| Charles Schwab | For | Against * | For |
| Nuveen and TIAA | For | Against * | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | For | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | For | Against * | For |
| Goldman Sachs | For | Against * | For |
| PGIM and Prudential | For | For | For |
| Northern Trust and FlexShares | No report | For | No report |
| SEI | For | Against * | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | For | Against | For |
| Voya | Abstain or withhold * | Against * | For |
| Nationwide | Abstain or withhold * | Against * | For |
| Victory Capital | Abstain or withhold * | Against * | For |
| Brighthouse Funds | Abstain or withhold * | Against * | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| Columbia Threadneedle | Abstain or withhold * | Against * | For |
| BNY Mellon | No report | Against * | No report |
| Principal | Abstain or withhold * | Against * | For |
| Pacific Life funds | For | Against * | For |
| Global X | For | Against * | For |
| Federated Hermes | For | Against * | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | Abstain or withhold * | Against * | For |
| Janus Henderson | No report | Against * | No report |
| Neuberger Berman | No report | Against * | No report |
| Natixis and Loomis Sayles | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Arcutis Biotherapeutics, Inc. meeting?
230 Form N-PX filers reported votes at the meeting of 14 Jun 2024. On say-on-pay, 169 of 218 voted against management (77.5%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Arcutis Biotherapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Arcutis Biotherapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Arcutis Biotherapeutics, Inc. with a meeting date within three days of 14 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.